SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 2,631.39 |
Enterprise Value ($M) | 2,759.96 |
Book Value ($M) | 77.69 |
Book Value / Share | 0.11 |
Price / Book | 33.87 |
NCAV ($M) | 64.45 |
NCAV / Share | 0.09 |
Price / NCAV | 40.83 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -2.17 |
Return on Assets (ROA) | -0.93 |
Return on Equity (ROE) | -4.86 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 9.30 |
Current Ratio | 9.30 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 189.71 |
Assets | 202.95 |
Liabilities | 125.26 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -88.73 |
Net Income | -614.93 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -76.76 |
Cash from Investing | -587.77 |
Cash from Financing | 86.51 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D/A | Zanganeh Maky | 5.27 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
952,885 | 4,250,280 | 22.42 | |
263,014 | 1,175,004 | 22.38 | |
615,583 | 2,987,043 | 20.61 | |
373,580 | 1,843,144 | 20.27 | |
(click for more detail) |
Similar Companies | |
---|---|
SGMT – Sagimet Biosciences Inc. | SIGA – SIGA Technologies, Inc. |
SLGL – Sol-Gel Technologies Ltd. | SNSE – Sensei Biotherapeutics, Inc. |
SPRY – ARS Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io